骨髓瘤展望：2024年革新疗法或推动2030年全球骨髓瘤药物市场规模增至330亿美元

增至330亿美元。尽管同期百时美施贵宝旗•生存期大幅延长：得益于加速批准的药物，新诊断患者的中位生存期已从1990•更多新药将会上市：随着强生、阿斯利康和吉利德-Arcellx推出工程化T细胞(CAR-T)和双抗等免疫重定向疗法，骨髓瘤患者的生报告主要内容：我们利用彭博行业研究的专有交互式市场规模测算模型和情景分析工具，并基于详细的流行病学模型、临床数据评估以及数据物市场规模的增长给出了相关预测。这些工具可通过彭博终端获利分析师的独家研究成果包括他们对潜在仿制药1Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024234章节8.分析师联系方式：SamFazeliAudeGerspachermfazeli@agerspacher@+44—20-35250457+1-212-617-30682Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024中就有9.7人罹患多发性骨髓瘤。骨髓瘤富裕国家的发病率更高，但这可能是因为这些国家的诊断率更高、诊断能力更强为全球骨髓瘤药物市场最大的药企（以销售额计），但目前面临仿制药竞争示，仿制药对该公司美国市场销售的侵蚀将在Abecma，因此更受欢迎。但我们的分析显示著以及CAR-T疗法不容易获取，强生Tecvayli的销售不断增长。我们的情3Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024章节2.值得关注的催化剂对骨髓瘤药物而言，最重要的短期临床催化剂将是今年待公布的以下临床试验数•2024年下半年：吉利4Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.202420年来治疗效果首次出现重大变化疾病概述小残留病灶(MRD)作为替代终点的情况下。最近，CAR-T期患者的希望。随着小分子免疫调节剂来那度胺和泊马度胺以及蛋白酶体抑场上销售，而其他三款药物的加速批准则被撤回，原因分别为副作用(Pe5Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024随着时间推移，缓解率逐步提高，尤其是使用新型进一步提高了缓解率。近期获批的双特异性抗体将缓解率（Carvykti和Abecma）将6Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024医生在治疗多发性骨髓瘤时会考虑许多因素。新诊断患者的件。除了患者的年龄和身体状况外，医生还必须考虑合并症。例如，周围神经病变疾病相关因素包括经过前期治疗后的无疾病间隔时间以及是否存在高风险标志物。少线的治疗，以及是否某种药物的治疗无效，7Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024患者进入下一个治疗线时脱落率较高，尤其是后线治疗患者。科医生调查显示，52%的二线治疗患者会转入三线治疗，39%会转入四线治疗。四线治疗，潜在原因包括疾病多次复发导致治疗成本较高、复发患者的治疗选择8Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024进入新治疗线时患者进入新治疗线时患者的脱落率较高。多发性骨髓瘤的发病率呈上升趋势，不同地区的发病率存在差更高，但这可能是因为这些地区的诊断率更高、诊断能力更强，而且患者还可使用博行业研究的全球多发性骨髓瘤模型主要关注美国、欧洲和日本，因为这些地区的种族也是一个重要因素。非裔美国人患骨髓瘤的风险是白人的两倍，但在所有试9Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024财富、种族和性别是重要的风险因素。除了遗传学外，还有其他三个风险特征：伴髓外病变（肿瘤长在骨Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024较高的治疗相关成本给医疗支付系统带来了较大负担，也是阻碍公长缓解期，如果能在早期治疗中使用，成本效益或将更高。然而Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024章节4.CELMoD药物需要更多数据但随着来那度胺仿制药变得越来越便宜，需要有更多数据才能提高它们的市场竞争须在更长的随访期内显示出更好的缓解深度并能提供维持治疗期间的安全性数据。百时美施贵宝的瑞复美和泊马度胺被广泛用于治疗多发性骨髓瘤，的显著提升。但公司面临这两种免疫调节剂(IMiD)的抗的患者可以考虑Mezi。然而，由于83%Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Iber维持治疗之后，缓解深度有所改善。然而，虽Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024需要更多数据才能评需要更多数据才能评估iber相比来那度胺的疗效是否有改善。来源：彭博行业研究维持治疗。其中的道理在于，CELMoD既能通过诱导Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024mezi和dex治疗的缓解率相当。此外，CFT7455联合dex方案的3-4级中性粒细胞减少症发生率较Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024章节5.Darzalex继续占据主导地位而基于这一前景，市场普遍预期到2030年，该药物的Darzalex改变了相关叙事，尤其是在一线治疗他药物联合使用，也支持其用于长期治疗，包括用于诱导治疗后的维持治疗。皮Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024MRD作为主要终点。试验数据似乎不够好），Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Darzalex进行维持治疗试验之前没有进行二次随机分组，而Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Darzalex与泊马度胺和dex联Isa-Pd组进行比较。鉴于疗效门槛较高且获取方便，Darzalex和Sarclisa在二线治疗中的使Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024以以Darzalex为基础的三联疗法是标准治效，27%的患者至少达到非常好的部分缓解(VGPR)，9%至少达到完全缓解，疗效好于SIRIUS和Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024``Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024章节6.CAR-T治疗骨髓瘤的革新疗法Carvykti（获得传奇生物授权）的疗效明显好CAR-T的早期数据来看，它们或将对Carvykti构成威胁。这两款药物似Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024CAR-TCAR-T治疗革命正在进行中胺、硼替佐米和dex(PVd)，但考虑到来那度药方案都不理想。正因为如此，Cartitude-4患者），Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Carvykti（2022年2月）和Abecma（2021年3月）首次获批是针对既往接受Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024于比较罕见，迟发性神经毒性（如帕金森病）很难比较，发病原因仍不清楚。Anito-cel和GC012F都能、新增两座工厂以及利用诺华的剩余产能。2026年以后，强Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024向社区医疗中心推广对增长很重要向社区医疗中心推广对增长很重要回患者体内的时间）为79天。随着产能格(OOS)产品的比例，而这些产品大部分都无法使Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024创造条件。在血液成分单采和淋巴细胞清除来源：NatureReviewsImmunology第22卷，第85-96页（2022年）），Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024来源：Poseida公司演示材料靶向与恶性细胞有关的抗原在CAR-T治疗期间，T细胞从患者体内采集之后，会被改造成能够表达嵌合抗原受体(CAR)的T细胞，以靶向与恶性细胞相关的抗原。该过程包靶向与恶性细胞有关的抗原来源：CancerGeneTherapy（2024年）CAR-T还旨在颠覆多发性骨髓瘤一线治疗的格局；目前移植。移植前会进行高剂量化疗（死亡率<2%且副作用严重），因此许多患者都选择Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024真正将带来显著变化的是，Cartitude-6试验中相比自Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024险可能最大。Talvey靶向骨髓瘤细胞上不同的靶点，因此面临们的风险/获益特征更好。这可能会给Tecvayli带来风险，尽管强生在多发性骨髓瘤药物市场的营销能Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024双抗药物销售额将随双抗药物销售额将随着疗效改善而激增Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024来源：彭博行业研究Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024一次（频率降低的时间更早），并且从第六个月进一步降低至每个月给药一次），感染可能致命，但通过免疫球蛋白(IVIG)替代疗法和其他预防性治疗措施可部分Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024通过调整给药频率降通过调整给药频率降低感染率Forimtamig都具有旨在提高疗效的特定设计ABBV-383与CD3结合的亲和力它们的抗体结构都有改进，都致力于延长半衰期，支持降低给药频率，从Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024根据一项真实世界研究，在接受Tecvayli术型医疗中心接受住院治疗，以应对这一过程中出现的副作用，之后可以转到社区心正在努力解决与CAR-T有关的毒副Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024测试。尽管随访期较短，但MajesTEC-2试验Darzalex+瑞复美+dex更深。要评估在早期治疗中TecvayNoportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024来源：彭博行业研究Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024章节8.用于多发性骨髓瘤治疗的抗体药物偶联物根据针对复发或难治多发性骨髓瘤患者的一项二期试验，Belanta和dex(Pd)的临床获益，该药先后退不过，由于28.2个月的随访期短于无进展Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024BlenrepBlenrep的罕见重新获批需要试验数据非常亮眼），另一个重要因素是毒性特征，尤其是眼毒性。由于试验中患者的给药频Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024的相关数据显示，虽然给药频率下降确实降低了不良事件的发生率，但改善似乎率并没有因为减少Blenrep剂量而下降。我们需要看到的是，DREAMM-8试验中3/Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024总缓解率为30%-40%。缓解率会如何随着时间推移而演变，Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.20248.3抗体药物偶联物的研发管线既不拥挤、也不丰富在开发中。另一款值得关注的抗体药物偶联物是阿斯利康的AZD0305（由礼新医药患者构成很大的负担）等双抗相比，该药物的副作用特征如何。Sorr抗体药物偶联物通过将与其偶联的化疗有效载荷集中在肿瘤部位，从而降低毒副Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024彭博行业研究的一项调查新显示，Darzalex在不断演变的多尤其是在一线和二线治疗中。Darzalex在诱导治疗后的维持医生在Darzalex治疗失败后会使用赛诺菲的Sarclisa。现在评估CAR-T在早期治疗和欧洲患者中近40%已在一线治疗中接受四联疗法。此外，Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024DarzalexDarzalex在不断演变的多发性骨髓瘤治疗领域占主导地位根据我们的美国和欧洲调查，符合干细胞移植条件的新诊断患者比例分别为45够健康，能够承受移植前的高剂量化疗。许多患者选择采集干细胞，但推迟移植手术的意愿很低，选择推迟的患者只有20%-30%最终在二线治疗中进行了Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024美国学术型医疗中心和社区治疗中心的医生对这一点 Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024根据彭博行业研究的调查，一线维持治疗后的无治深度出现改善。这表明最初几年新诊断患者的状态可能相对稳定，维持治疗的时间我们的调查显示，维持治疗期间疾病出现进展的患者占30%Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Darzalex是多发性骨髓瘤二线治疗的主要用药Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024患者治疗后处于缓解期的持续时间患者治疗后处于缓解期的持续时间彭博行业研究调查了50名在美国工作的在欧洲，彭博行业研究调查了50名在英国Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024加，但与双抗药物相比，后勤和成本仍是阻碍这两种这给新疗法创造了机会，尽管在对Darzalex治疗无效之后，医生可能仍会尝试使用Sarclisa。虽然这Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024来看，50%的患者仍将在三线治疗中使用CD个月）相对较长。另一个潜在原因是，在CARNoportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024欧洲的医生更倾向于欧洲的医生更倾向于改用Sarclisa。我们对美国血液肿瘤医生的调查结果显示，二线治疗结束后，Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024直到不久之前，CAR-T还仅被批准用于既往接受四线示，43%的三线治疗患者将接受CAR-T疗法（即Abecma和CaNoportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024我们的调查显示，只有39%的患者在三线治疗结束后会转入Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024在欧洲，在结束三线治疗后的骨髓瘤患者中，4Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024根据我们的欧洲调查，目前在治疗后线患者时，血液肿瘤医生使用的治疗方案Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024章节11.骨髓瘤药物市场概要根据彭博行业研究的计算，全球骨髓瘤药物市场每年将增长5.2%，2030年规模Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024彭博行业研究模型和彭博行业研究模型和市场普遍预期均显示CD38抗体将成为主流治疗药物我们预计，随着四联疗法和三联疗法的普及，Darzalex在Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024Noportionofthisdocumentmaybereproduced,scannedintoanelectronicsystem,distributed,publiclydisplayedorusedasthebasisofderivativeworkswithoutthepriorwrittenconsentofBloombergFinanceL.P.CopyrightandDisclaimernoticeonpage96appliesthroughout.©BloombergFinanceL.P.2024